menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Investigating DLL3-Targeted Immunotherapy: The Potential of T Cells to Fight SCLC

Details
Recommended

Overview

ReachMD Healthcare Image
RestartResume

Emerging modalities like T-cell engagers targeting delta-like ligand 3 (DLL3) are currently being investigated in small cell lung cancer. Here’s why.

  • Sponsored by

  • Overview

    T-cell engagers are currently being investigated for small cell lung cancer1 as they’re designed to engage the patient's own T cells to target a tumor-associated antigen on tumor cells.2 Delta-like ligand 3 (DLL3) is a potential therapeutic target for T-cell engagers due to its high expression on small cell lung cancer cells.3,4 Learn more about the potential of investigational T-cell engager immunotherapy targeting DLL3 in small cell lung cancer with Dr. Jennifer Caudle and Dr. Taofeek K. Owonikoko, who is Chief of the Division of Hematology/Oncology at the UPMC Hillman Cancer Center, and in the Department of Medicine.

    References:

    1. Einsele H, et al. Cancer. 2020;126:3192-3201.
    2. Yuraszeck T, et al. Clin Pharmacol Ther. 2017;101:634-645.
    3. Sabari JK, et al. Nat Rev Clin Oncol. 2017;14:549-561.
    4. Leonetti A, et al. Cell Oncol (Dordr). 2019;42:261-273.

    ©2023 Amgen Inc. All rights reserved. USA-757-80019 9/23

Schedule14 Jul 2024